Inherited Causes of Clonal Hematopoiesis in Multiplicity of Whole Genomes
|
By LabMedica International staff writers Posted on 29 Oct 2020 |

Image: Mutations in cell free DNA (cfDNA) or cells in the peripheral blood along with anemia or thrombocytopenia are the hallmark of myelodysplastic syndrome (MDS). The diagnosis of MDS is confirmed when mutations in hematopoietic cells are detected at relatively high levels (Photo courtesy of Genomic Testing Cooperative).
The age-related acquisition of somatic mutations that lead to clonal expansion in regenerating hematopoietic stem cell populations has recently been associated with both hematological cancer and coronary heart disease, and this phenomenon is termed clonal hematopoiesis of indeterminate potential (CHIP).
As the name CHIP suggests, this subpopulation in the blood is characterized by a shared unique mutation in the cells' DNA; it is thought that this subpopulation is "clonally" derived from a single founding cell and is therefore made of genetic "clones" of the founder. Simultaneous analyses of germline and somatic whole-genome sequences provide the opportunity to identify root causes of CHIP.
A team of scientists at the Broad Institute (Cambridge, MA, USA) and their colleagues analyzed high-coverage whole-genome sequences from 97,691 participants of diverse ancestries in the National Heart, Lung, and Blood Institute Trans-omics for Precision Medicine (TOPMed) programme, and identify 4,229 individuals with CHIP. They noted that the prevalence of CHIP increased with the age at which the blood samples were taken from participants, as well as with a history of smoking.
The investigators identified associations with blood cell, lipid and inflammatory traits that are specific to different CHIP driver genes. Association of a genome-wide set of germline genetic variants enabled the identification of three genetic loci associated with CHIP status, including one locus at TET2 that was specific to individuals of African ancestry. About three-quarters of individuals with CHIP had mutations in just three genes: DNMT3A, TET2, and ASXL1. Some CHIP characteristics, they noted, varied by driver gene mutation. For instance, JAK2 CHIP mutation carriers were generally younger than other carriers, and TET2 CHIP carriers tended to have increased interleukin-1β (IL-1β levels), while JAK2 and SF3B1 carriers had increased circulating IL-18.
Within a subset of this cohort, the team conducted a single-variant genome-wide association analysis to uncover germline variants linked to CHIP. Through their analysis and subsequent replication, they uncovered one variant in TERT that was associated with a 1.3-fold increased risk of developing CHIP, as well as a variant near both KPNA4 and TRIM59 that was associated with a 1.16-fold increased risk and a variant near TET2 that was associated with a 2.4-fold increased risk of developing CHIP.
The authors concluded that germline genetic variation shapes hematopoietic stem cell function, leading to CHIP through mechanisms that are specific to clonal hematopoiesis as well as shared mechanisms that lead to somatic mutations across tissues. The study was published on October 14, 2020 in the journal Nature.
Related Links:
Broad Institute
As the name CHIP suggests, this subpopulation in the blood is characterized by a shared unique mutation in the cells' DNA; it is thought that this subpopulation is "clonally" derived from a single founding cell and is therefore made of genetic "clones" of the founder. Simultaneous analyses of germline and somatic whole-genome sequences provide the opportunity to identify root causes of CHIP.
A team of scientists at the Broad Institute (Cambridge, MA, USA) and their colleagues analyzed high-coverage whole-genome sequences from 97,691 participants of diverse ancestries in the National Heart, Lung, and Blood Institute Trans-omics for Precision Medicine (TOPMed) programme, and identify 4,229 individuals with CHIP. They noted that the prevalence of CHIP increased with the age at which the blood samples were taken from participants, as well as with a history of smoking.
The investigators identified associations with blood cell, lipid and inflammatory traits that are specific to different CHIP driver genes. Association of a genome-wide set of germline genetic variants enabled the identification of three genetic loci associated with CHIP status, including one locus at TET2 that was specific to individuals of African ancestry. About three-quarters of individuals with CHIP had mutations in just three genes: DNMT3A, TET2, and ASXL1. Some CHIP characteristics, they noted, varied by driver gene mutation. For instance, JAK2 CHIP mutation carriers were generally younger than other carriers, and TET2 CHIP carriers tended to have increased interleukin-1β (IL-1β levels), while JAK2 and SF3B1 carriers had increased circulating IL-18.
Within a subset of this cohort, the team conducted a single-variant genome-wide association analysis to uncover germline variants linked to CHIP. Through their analysis and subsequent replication, they uncovered one variant in TERT that was associated with a 1.3-fold increased risk of developing CHIP, as well as a variant near both KPNA4 and TRIM59 that was associated with a 1.16-fold increased risk and a variant near TET2 that was associated with a 2.4-fold increased risk of developing CHIP.
The authors concluded that germline genetic variation shapes hematopoietic stem cell function, leading to CHIP through mechanisms that are specific to clonal hematopoiesis as well as shared mechanisms that lead to somatic mutations across tissues. The study was published on October 14, 2020 in the journal Nature.
Related Links:
Broad Institute
Latest Molecular Diagnostics News
- Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
- Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
- Researchers Uncover Distinct Chromosome Signature in Aggresive ALT Cancers
- Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
- Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
- Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer
- Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
- Multi-Cancer Test Boosts Detection When Added to Standard Screening
- Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia
- Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer
- Blood Protein Markers Flag Multiple Sclerosis Risk Years Before Diagnosis
- Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
- Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
- Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
- Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests
- Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








